Fair comments, but it was pretty clear at the outset that the magnitude of effect on which the power calculations for BETonMACE were based were optimistic. I always felt uncomfortable about that aspect of the trial. A more realistic predicted effect (say 20%) would have meant more patients and/or a longer follow-up. But by now, we might have had a statistically significant result. Hopefully, the FDA will prevent the same mistake happening in BoM2.

I don't think DM is medically qualified. Norman Wong and Jan Johansson are, but not Don. Jan Johansson is also CEO of Artery Therapeutics, by the way.